Vident Investment Advisory’s Amicus Therapeutics FOLD Stock Holding History

Vident Investment Advisory’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,304	Closed	-$103K	–	1233
2022 Q3	$103K	Buy	+10,304	New	+$115K	﹤0.01%	1054
2022 Q2	–	Sell	-12,783	Closed	-$121K	–	1317
2022 Q1	$121K	Sell	12,783 -2,331	-15%	-$21.9K	﹤0.01%	1224
2021 Q4	$175K	Buy	+15,114	New	+$168K	﹤0.01%	1149
2021 Q3	–	Sell	-21,043	Closed	-$203K	–	1184
2021 Q2	$203K	Buy	+21,043	New	+$205K	0.01%	1056

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vident Investment Advisory's FOLD Position: Q4 2022 in Review

Vident Investment Advisory sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 10,304 shares — an estimated $103K sold.

Vident Investment Advisory first reported a position in FOLD in Q2 2021 and held it in 4 quarters. The position peaked at $203K in Q2 2021. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

Vident Investment Advisory reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
Vident Investment Advisory sold 10,304 Amicus Therapeutics shares in Q4 2022, an estimated $103K.
Vident Investment Advisory first reported a position in Amicus Therapeutics in Q2 2021 and held it in 4 quarters.
Vident Investment Advisory's Amicus Therapeutics position peaked at $203K in Q2 2021.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.